Brief: Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability
25/11/2024 14:15
Nov 25 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES PRECLINICAL PHARMACOKINETIC STUDIES OF
EB-003 SUPPORT ORAL BIOAVAILABILITY, DEMONSTRATE BRAIN
PENETRATION, AND SHOW NO EVIDENCE OF HALLUCINATION-LIKE BEHAVIOR
* ENVERIC BIOSCIENCES : PLANS TO SUBMIT EB-003 IND
APPLICATION TO
FDA IN H2 OF 2025
Source text: ID:nBw2bNtmJa
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003